FDA Inspection 1208297 — Acrostak (Schweiz) AG

Acrostak (Schweiz) AG — FEI 3005086865

The FDA completed an inspection of Acrostak (Schweiz) AG on June 15, 2023 in Winterthur. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Devices.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
June 15, 2023
Fiscal Year
2023
Product Type
Devices
Project Area
Compliance: Devices
Location
Winterthur (Switzerland)

Citations

IDCFRDescription
1471321 CFR 820.198(a)Lack of or inadequate complaint procedures
311921 CFR 820.75(b)Lack/Inad procedure-Monitoring/Control of Validated Proces
328221 CFR 820.90(a)Nonconforming product, Lack of or inadequate procedures
367821 CFR 820.30(g)Design Validation - Risk analysis not performed/inadequate
54121 CFR 820.70(c)Environmental control Lack of or inadequate procedures
54621 CFR 820.75(a)Lack of or inadequate process validation